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Innovations in Care
Harnessing Teams and Technology to Improve Outcomes in
Infants With Single Ventricle
Girish Shirali, MBBS; Lori Erickson, RN, CPNP, APRN; Jonathan Apperson, BS;
Kathy Goggin, PhD; David Williams, MPH; Kimberly Reid, MS;
Andrea Bradley-Ewing, MPA, MA; Dawn Tucker, DNP, RN, CPNP-AC; Michael Bingler, MD;
John Spertus, MD, PhD; Leslie Rabbitt, MPH; Richard Stroup, BS
Abstract—Infants with single ventricle require staged cardiac surgery, with stage I typically performed shortly after birth,
stage II at 4 to 6 months of age, and stage III at 3 to 5 years of age. There is a high risk of interstage mortality and
morbidity after infants are discharged from the hospital between stages I and II. Traditional home monitoring requires
caregivers to record measurements of weight and oxygen saturation into a binder and requires families to assume a
surveillance role. We have developed a tablet PC–based solution that provides secure and nearly instantaneous transfer of
patient information to a cloud-based server, with the capacity for instant alerts to be sent to the caregiver team. The cloudbased IT infrastructure lends itself well to being able to be scaled to multiple sites while maintaining strict control over
the privacy of each site. All transmitted data are transferred to the electronic medical record daily. The system conforms to
recently released Food and Drug Administration regulation that pertains to mobile health technologies and devices. Since
this platform was developed in March 2014, 30 patients have been monitored. There have been no interstage deaths. The
experience of care providers has been unanimously positive. The addition of video has added to the use of the monitoring
program. Of 30 families, 23 expressed a preference for the tablet PC over the notebook, 3 had no preference, and 4
preferred the notebook to the tablet PC.
Key Words: caregivers ◼ congenital ◼ mortality ◼ survival ◼ telemedicine
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Goals and Vision of the Program

Ghanayem et al6 initiated a program of home surveillance for
babies who had undergone the Norwood procedure. Families
were discharged with a weight scale, pulse oximeter, and a
binder for logging daily measurements. Although home monitoring was associated with improved interstage survival, interstage mortality remains a significant problem, comparable in
incidence to the mortality of the Norwood procedure. Today,
interstage mortality ranges between 2% and 20% with almost
75% of deaths occurring suddenly.2,7,8 In recognition of this, in
2011, the National Pediatric Cardiology Quality Improvement
Collaborative (NPC-QIC) focused on improvement in interstage mortality.9 Today, a large majority of programs use home
monitoring during the interstage period.9 The interstage period
is now known to be strongly associated with mortality, morbidity, and hospitalizations in babies with all forms of single
ventricle, including those who have undergone forms of initial
surgical palliation other than the Norwood procedure.10 Consequently, many programs have expanded the scope of their
interstage monitoring programs to include children with all
forms of single ventricle. During the past few years, the focus

Babies who are born with hypoplastic left heart syndrome
require staged surgical palliation, which involves 3 operations, the first of which (the Norwood procedure) is performed
shortly after birth.1 A second operation (the superior cavopulmonary anastomosis) is typically performed between 4 and 6
months of age, and a third operation (the Fontan procedure)
between 3 and 5 years of age. Hospital mortality after the
Norwood procedure remains the highest among common congenital heart procedures, ranging between 7% and 19%.2,3 An
analysis of resource utilization for common structural heart
defects has shown that the Norwood procedure is associated
with the highest cost, and the third longest length of stay.4

The Interstage Period
The period between discharge after the Norwood procedure
and completion of the second stage surgery—the interstage
period—is one during which these babies are at risk for sudden death at home. Before 2000, interstage mortality after the
Norwood procedure ranged between 15% and 20%.5 In 2000,
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of interstage monitoring has also expanded from improving
survival to improving growth and nutrition.11 These changes
to the care model have already led to some improvements in
outcomes.12,13

Limitations of the Existing System
The system of interstage monitoring that was proposed by
Ghanayem et al6 places the responsibility for monitoring,
interpretation of monitoring data, and contacting providers on
patients’ families. This has the potential for missing important
clinical cues that can delay care, in addition to potentially adding to the psychological burden for parents. In response, some
teams have taken on an active role where they initiate phone
calls, text messages, or other similar mechanisms to contact
families, obtain information from the families’ log books, and
then transcribe it into a spreadsheet. The teams review the
spreadsheets periodically to guide management. Delays and
redundant data entry are implicit to this process. Nevertheless,
it lays the conceptual foundation for systematically collecting data on multiple patients, with the potential for generating
new knowledge.

The Vision

Downloaded from http://ahajournals.org by on July 26, 2019

Although the past decade has seen paradigm shifts in mobile
technology, interstage monitoring has not changed, barring a
few exceptions with varying results.14,15 To improve interstage
outcomes in a manner that harnesses the power of teams, technology and automation, we conceived of a solution that was
based on remote monitoring and ensured continuous, connected care for patients and their families. Our vision was that
instead of a binder, the family would enter data (pulse oximetry, weight, and other information) into a mobile device with
near-instant connection to an enterprise database and the ability to perform automated analytics and graded notifications to
the care team, while also, as a secondary objective, laying the
foundation for future outcomes research.

Local Challenges in Implementation
The concept of re-engineering home monitoring required a
full understanding of all of the components and workings of
the current model, the articulation of a clear vision for an idealized future state, and the development and implementation
of a solution that would duplicate all of the desirable features
of the current model, remove the less-desirable features, and
augment the process with new capabilities. While this process
started as an idea in 2012, it remains ongoing and iterative and
continues to evolve in scope over time and in response to field
testing and feedback from end-users.
An interstage monitoring program had existed in our
center since 2011, but it had deficiencies that we addressed
while the new platform was being developed. The team and
care model for managing the interstage period were structured
loosely and relied on individuals who had many other unrelated responsibilities. There was no consistency in terms of the
nature of home monitoring, and the availability of equipment
was dictated by whether insurers would cover the costs. Our
concept was for a care team that would be focused on the specific area of interstage mortality, potentially with secondary

responsibilities in complementary areas. The program also
needed a unique identity, with a name that made sense and
supported team cohesiveness and purpose.
To move the new platform from concept to execution,
it was critical to obtain institutional support and funding.
Decisions such as the choice of the operating system for the
mobile platform, the specific device(s) that would be used,
regulatory issues around patient enticement, confidentiality,
compliance, types of data transmission, nature and capabilities of the database that would receive and interpret the data,
specifics of data visualization by the clinical team, and the
nature of integration with the electronic medical record all had
to be addressed. A particularly important feature sought by the
team was to add in daily high-definition videos of the babies.
The goal was to enable teams to have access to longitudinally
collected virtual physical examinations, to potentially help
detect subtle changes in the baby’s appearance and breathing
pattern. Because our electronic medical record does not provide the ability to store videos, we had to decide where the
videos would be housed.

Design of the Initiative
In early 2013, we started working toward a new model of care
named Cardiac High Acuity Monitoring Program (CHAMP).
Programmatic goals included ensuring that these patients’
families would receive uniform education before discharge,
and that they would be cared for by a dedicated, focused group
of providers who called families on a weekly basis, in addition
to proactive contact for any emerging clinical problems. This
team initially consisted of an advanced practice registered
nurse and a nurse coordinator. Over time, other key components were added, including 2 dedicated pediatric cardiologists, a Medical Director, a social worker, and a dietician. We
ensured that all patients consistently went home with a pulse
oximeter and a weight scale. The contemporaneous focus on
the interstage period by NPC-QIC provided us with the framework to institute—and periodically revisit and modify—best
practices.11,12
We were fortunate to obtain funding from a philanthropic
source (the Claire Giannini Fund (http://www.clairegianninifund.org/) for the development and implementation of the
tablet PC platform. Our presentations of the tablet PC concept to institutional leadership were well-received, which was
critical to insure ongoing support after grant funding ended.
To develop a solution that would combine technical and clinical practicality, we built a team that combined both medical
informatics and clinical expertise, with input on an as-needed
basis from our legal office, hospital compliance leadership,
and other key stakeholders.

Decisions and Reasoning
We decided to maintain complete control over hardware
and software, and to limit ourselves to a single platform. We
determined that a Windows-based tablet PC would provide
the necessary functionality while allowing us to benefit from
our years of experience with Microsoft Windows software
development. At this stage of design and feasibility testing,
we also did not want to deal with the burdens of developing
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Figure 1. This figure provides examples
of the caregiver interface for the Cardiac
High Acuity Monitoring Program tablet PC.
Top, Screen shot of the home page for
the touch screen interface. Each of the 6
icons is touch-responsive and opens up the
appropriate screen for data entry. Bottom,
The contents of the screen that pertains to
oxygen saturation. This screen defaults to
the current time and date stamp, but the
caregiver can change those if they are making a late entry for a previous measurement.
The Comments box provides for the entry
of free text, where the caregiver can type in
any comments that they decide are relevant.
The caregiver has the opportunity to delete
or edit an entry for 5 minutes after they save
it; after 5 minutes, the data automatically
uploads to the web server. A static, preprogrammed reminder is seen in red at the
bottom of the screen. This serves to remind
the caregiver that the red flag for low oxygen saturations is 70%. Regardless of what
number the caregiver enters, the tablet does
not interpret the entry; it passes information on to the HeartCenter database. The
database is programmed to identify values
that are out of range and to send appropriate alerts to the coordinator or care-provider
who is on call.

our software on numerous operating systems (iOS, Android,
etc.) and compatibility testing for every new software release
of each platform. To minimize potential disparities in access
and to ensure that all patients would qualify for our program
without requiring their own wireless internet or cellular service, we selected tablets with built-in cellular capability at
no charge to the family. This form of internet access is used
regardless of whether the family has alternative methods to
access the internet. Consistency of the route of transmission
ensured that we were able to maintain security of transmitted data. To address the issue of patient enticement, the tablet
PC was programmed into kiosk mode, which only allows it
to be used for a single purpose (interstage monitoring). Our
choice of cellular service provider was driven by the quality
and extent of coverage in our geographic area, although this is
configurable to different carriers and environments. We used
feedback from the clinical team, parents, and from our institution’s office for family-centered care to refine and optimize
the appearance and flow of the user interfaces for both the
families and the CHAMP clinical team. We then developed a
Spanish version of CHAMP to meet the needs of our Spanishspeaking families. Examples of the CHAMP tablet user interface for families are shown in Figure 1.

Use of Wireless Technologies
Next, we addressed the question of whether to use Bluetooth
(or other wireless) peripheral devices, such as weight scales and
pulse oximeters, to simplify the transmission of pulse oximetry
and weight data to the tablet PC, or to use manual entry of data.
There were limited choices for wireless transmission of data
from peripheral devices. We initially used a pulse oximeter with
Bluetooth capability, but the only such model that could be used
for babies was one that did not have an audible alarm system or
a visible waveform, and it had not been validated for cyanotic
infants. We could only find 2 manufacturers of Food and Drug
Administration-approved wireless digital baby weight scales. Of
these, 1 company would not allow direct access to patient data;
instead, they wanted us to use data that were routed through
their servers, which raised issues of cost, confidentiality, speed,
and reliability. Another manufacturer used proprietary wireless
technologies that proved unwieldy for daily use by caregivers.
We were also aware of emerging Food and Drug Administration
guidance about the nature of mobile monitoring devices, which
led to a level of uncertainty about the level of Food and Drug
Administration oversight that may be needed if we were to opt
for wireless transfer of data from peripheral devices.16 For all of
these reasons, we decided not to use any peripheral devices and
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to limit the scope of the CHAMP tablet to being a passive conduit for patient monitoring, using manual entry into data fields.

Data Encryption and Warehousing
Our informatics team developed highly encrypted methods for
the transmission and storage of data in a manner that is Health
Insurance Portabilty and Accountability Act compliant. To be
able to extend the application of CHAMP beyond the confines of our own center, we developed secure mechanisms for
the transfer of data that would maintain the confidentiality of
each participant and site, while enabling seamless analysis of
cumulative data. We ultimately selected the Microsoft Azure

platform, an industry-standard cloud-based solution that lends
itself well to high levels of security and encryption.
Several years ago, we began developing a proprietary
and patented software and data warehouse solution known as
HeartCenter. Its main purpose is to collect information from a
number of other hospital systems, manage business processes
associated with a large congenital cardiology and cardiovascular
surgery department, and allow users to visualize and analyze all
data in a coherent and consistent fashion. Information such as
patient demographics and visit details from our hospital information system, laboratory results, measures from our cardiology
picture archiving and communication system, operating room
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Figure 2. This illustration depicts details of the flow of information between the home caregiver, cloud-based web service, and care
teams. Connection between the tablets and the web service occurs through a secure Secure Sockets Layer (SSL) connection. The web
service accepts data from the tablets and stores it in the cloud. It does not provide any data to the tablet except an acknowledgment
that the data were successfully saved. Each data point is hashed to verify the identity of the source. The database where data are stored
resides in the Azure cloud, and all protected health information is encrypted. A secret encryption/decryption key is created for each
facility (Rijndael cipher), and each row of data is individually encrypted by a uniquely generated Initialization Vector. This eliminates the
possibility of deducing the value of frequently repeating patterns within data sets, such as male/female or letter-based frequency distributions, even if unauthorized access to the data were gained. The Cardiac High Acuity Monitoring Program (CHAMP) website is password
protected, and each institutional user, once validated, is restricted to seeing his/her institution’s patients only. Users’ passwords are
uniquely salted and hashed so that all passwords saved in the database are unique and unrecoverable. All access to the site is forced to
a secure (SSL) channel. All communication between tiers is secured with SSL encryption using a 4096-bit certificate. HL7 transactions
are restricted to secure file transfer protocol. Communication of alerts to devices that cannot be secured—such as text pagers, e-mail,
and short message service—is limited to only as much information as is necessary for the clinician to be able to identify the subject of the
alert. An HL7 interface provides for all CHAMP data to be uploaded daily into the electronic medical record.
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Table 1.

List of Red Flag Clinical Concerns and Instant Alerts

Red flags
 Any behavior or bodily change that worries the caregiver
 Temperature >101°F
 Does not gain an average of 20 g/d >7 days or has 3 days of weight loss
 Increased work of breathing or stopping to breathe during feeding
 Bloody stool
 Feeding difficulty, increased sweating during feeds, or excessive
spitting up
 Vomiting or diarrhea (>3 episodes in 24 h)
 Irritability/wont calm or decreased response to you
 Low oxygen saturations (<70%)
 Fewer than 4 wet diapers per day
 Problems with the child’s feeding pump or pulse oximeter

to view videos within Xcelera, excluded the soundtrack from
the recordings. In field testing, the CHAMP team found significant added value in hearing the sound of the baby breathing. Therefore, we changed the plan and decided to house the
video as a standard AVI file in the HeartCenter database itself,
within each patient’s individual folder.
We collected all data under an Institutional Review Boardapproved protocol, with an additional consent form that pertains to assignment of rights and release of images for the
video recordings that are retained in the CHAMP system.
As designed, the CHAMP tablet PC serves as a passive collector of data that is sent to the enterprise database (HeartCenter),
where analytics are performed to designate appropriate alerts to
the CHAMP team. It does not interact with the family or the
patient, and does not respond to any values that are entered. Every
24 hours, HeartCenter automatically outputs all CHAMP data to
our electronic medical record (Cerner) using an HL7 interface.

Instant alerts

Analytics and Alerts

 Oxygen saturations <70% or >93%

Our program uses the red flag alerts that have been adopted by
NPC-QIC.12 These are listed in Table 1. CHAMP team members
noted that while each of these red flags is an important indicator
of an underlying problem, some are more urgent than others.
The connection of the CHAMP tablet to an enterprise database
provides the ability to instantly alert the care team about specific issues. In taking advantage of this capability, a short list of
alerts, termed instant alerts, was developed (Table 1). In addition, an instant alert is triggered if the caregiver indicates that
they are concerned for any of the reasons listed in Table 1.

 Heart rate <90 bpm or >180 bpm
 Bloody stool
 Three episodes of emesis in 24 h
 Three diarrheal stools in 24 h
 Concerns: Caregiver is concerned because the baby is:
  Just not him/herself
Downloaded from http://ahajournals.org by on July 26, 2019

  Having a fever >101°F
  Working harder to breathe
  Having feeding trouble or sweating during feeds
  Looking swollen with fewer wet diapers
  Looking bluer or needing oxygen
  More tired today or not waking up well
  In pain despite all the normal interventions
CHAMP indicates Cardiac High Acuity Monitoring Program. Caregivers are
trained to contact the CHAMP team if their child exhibits any red flag. The
CHAMP team is instantaneously notified in the event of an instant alert.

and perfusion details, and a host of other data are collected and
displayed in real time and then stored in our data warehouse for
quality improvement and research purposes. We determined
early on that HeartCenter was an ideal infrastructure within
which to store and visualize CHAMP measures, alerts, and
videos. An interface was developed between HeartCenter and
CHAMP. As a result, we gained access to a large amount of associated patient data for each patient who was monitored at home.
A web-based version of the HeartCenter software was designed,
and the cloud-based architecture was then developed in preparation for our plans to enable other sites around the country to be
able to use the CHAMP system. The specifics of data transmission and warehousing are demonstrated in Figure 2.
The addition of video recordings posed a challenge. Our
initial plan had been to house videos in our echocardiography image management system (Xcelera, Philips Medical
Systems). Unfortunately, the addition of a Digital Imaging
and Communications in Medicine wrapper, which is required

Implementation of the Initiative
It took 2 years to move CHAMP from concept to reality. Once
the platform was developed and stable, the first step was to
prove feasibility and reliability. This was done in early 2014 by
asking 2 families to volunteer to perform dual entry of home
monitoring data: once into CHAMP, and, separately, into the
(then state-of-the-art) logbook. At the end of 1 month, each
field of information in the logbook was matched with the corresponding field that had been received through the tablet PC.
This study revealed that data transfer was feasible and reliable,
as there were no errors detected. The development of automated reporting and calculations, presenting data in a manner
that was the most efficient for the clinical team, was an iterative process driven primarily by dialog between the clinical team
and the informatics team. It resulted in the type of graphic display that is demonstrated in Figure 3, with multiple overlays of
data from CHAMP that were designed in a manner that makes
clinical sense. In addition, the CHAMP team now receives an
automated Summary Report of all data received on all patients
every morning. This report has computer-generated highlights
for every value that is out of a configurable, predefined range. It
enables the clinical team to rapidly review all active patients for
any potential problems. Specifics about the exact values for each
field that would trigger an instant alert to the CHAMP team were
discussed, implemented, and refined until they were optimized.

Response to Caregivers’s Input
Caregivers are instructed in the use of the tablet PC in the
last few days of their initial hospitalization, before assuming
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Figure 3. Data visualization using CHAMP (Cardiac High Acuity Monitoring Program). Each dot represents a discrete data element that
was received. Time is on the x axis, oxygen saturation is on the left-sided y axis (red dots) and weight is on the right-sided y axis (blue
dots). Each of the purple dots represents a video. Each red flag is charted. The first (upright) green triangle on the left represents a clinic
visit that was initiated based on clinical cues. Each pair of inverted green triangles, connected by dotted lines, represents an inpatient
admission. In infants with single ventricle who are interstage, baseline oxygen saturations are typically around 80%. In this case, saturations started in the mid to high 80%s, stabilized around 80% and were then elevated significantly in late April and early May 2014. This
was associated with a slowdown in weight gain. At the end of the first week of May, the baby was diagnosed with recoarctation of the
aorta and underwent balloon angioplasty of recoarctation. Oxygen saturations dropped to baseline, and weight gained improved almost
immediately thereafter.
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responsibility for monitoring. Families have had varying levels of interest in knowing what the graphic trends on their
babies look like; of those who have wanted data, some have
wanted to see graphs, whereas others have preferred tables. In
response, we have implemented the capability for automatic
Table 2.

e-mails that send both graphic and tabular summary data
on a weekly basis to those families who express a desire to
receive this information. The majority of caregivers have readily accepted the CHAMP platform regardless of their level of
technical sophistication or language preference. There are

Interstage Outcomes and Resource Utilization Before and After Initiation of CHAMP

Total number of patients discharged with interstage monitoring (n=83)

Before Initiation of CHAMP

After Initiation of CHAMP

53

30

P Value

Age at neonatal discharge in months, median (IQR)

1.43 (0.95, 1.93)

1.2 (0.67, 2.1)

0.365

Age at the end of interstage period (stage II surgery, death, or transplant), median (IQR)

7.23 (5.63, 9.6)

5.85 (4.93, 7.33)

0.021

No. of interstage days per patient (mean±SD)

190±99

143±55

0.006

Total number of interstage days

10 095

4275

Interstage mortality for all single ventricles (%)
Interstage mortality for HLHS (%)
Total number of unplanned readmissions
No. of unplanned readmissions per patient per 100 interstage days, median (IQR)
Total number of unplanned readmission days
No. of unplanned readmission days per patient per 100 interstage days, median (IQR)
Total number of unplanned readmission ICU days
No. of unplanned readmission ICU days per patient per 100 interstage days, median (IQR)
Total unplanned inpatient charges (US$)
Unplanned inpatient charges per patient per 100 interstage days, median (IQR) (US$)
Total number of visits to the emergency room
No. of emergency room visits per patient per 100 interstage days, median (IQR)
No. of patients who underwent stage II (Glenn) during unplanned readmission

9 (17%)

0 (0%)

0.023

6/33 (18%)

0/14 (0%)

0.159

91

43

0.63 (0, 1.64)

0.73 (0.46, 1.41)

1174

481

3.05 (0, 18.6)

4.85 (0.52, 13.9)

633

233

0 (0, 8.4)

1.39 (0, 5.49)

13 200 000

5 665 285

20 486 (0, 178 762)

41 712 (1924, 164 311)

104

33

0.7 (0, 1.64)

0.63 (0, 1.38)

7

3

CHAMP indicates Cardiac High Acuity Monitoring Program; HLHS, hypoplastic left heart syndrome; ICU, intensive care unit; and IQR, interquartile range.

0.75

0.613

0.52

0.805

0.41
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ongoing studies of caregivers’ feedback for both the logbook
and the tablet PC.

Success of the Initiative
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Starting in May 2014, the CHAMP tablet PC became the
standard of care for interstage monitoring of babies with single ventricle at our institution. We have followed 30 babies
interstage using CHAMP. These consist of 14 babies with
hypoplastic left heart syndrome who underwent a Norwood
or hybrid procedure, 12 with right ventricular hypoplasia and
pulmonary atresia who underwent an aortopulmonary shunt,
and 4 who had a balanced circulation and were discharged
without requiring neonatal surgery. Input from families has
been used to refine the capabilities of CHAMP. Details on the
quantity of data collected are summarized in Table 1 (Appendix I in the Data Supplement).
We compared outcomes and resource utilization with
CHAMP tablet monitoring (April 2014—current, 30 patients)
to the preceding 3 years, during which the interstage monitoring team and program were being optimized (January
2011 to March 2014, 53 patients). Clinical data were collected using chart review, and charge data were obtained from
our hospital’s financial system (GE Centricity Business).
Outcomes and resource utilization for each of these periods
are summarized in Table 2. χ2 and Fisher exact test were
used to compare categorical variables. Either the t test or the
Mann–Whitney U test was used to compare continuous variables. Neither the distribution of diagnostic subtypes of single
ventricle nor the age at neonatal discharge differed between
phases. Contemporaneously with the use of the CHAMP tablet, median age at the end of the interstage period decreased
significantly from 7.23 months to 5.83 months (P=0.026),
and therefore, so did the duration of the interstage period per
patient. Interstage mortality has decreased in all patients with
single ventricle (17%–0%, P=0.025) as well as in patients with
hypoplastic left heart syndrome (18%–0%, P=0.159) since the
initiation of CHAMP. Although markers of resource utilization such as number of unplanned readmissions, readmission
days, intensive care unit days, inpatient charges, and emergency room visits per patient have improved with the use of
the CHAMP tablet, these improvements do not meet statistical
significance. We conducted additional analyses of these markers of resource utilization by controlling for the varying duration of the interstage period (by calculating each marker of
Table 3.

resource utilization per 100 interstage days per patient), which
also did not reveal significant differences between groups. We
recognize that there are serious limitations to this retrospective study. Given our results on the feasibility of the system,
further studies are needed to critically compare CHAMP to
paper, as well as to evaluate human–computer interaction
from both the caregiver and the care-provider perspectives.
Anecdotally, CHAMP clinical team members report that
they spend less time collecting data and more time making
decisions. The summary report provides rapid access to information and better time management, enabling the team members to focus their efforts on subjects with concerning trends.
The addition of video has been perceived to be an important
advantage. Not only does it enable the CHAMP team to evaluate the baby’s breathing pattern but it also provides an unanticipated glimpse into the interactions between the baby and
the caregiver in the baby’s home environment: an interaction
that has, until now, not been part of the diagnostic toolset.
Information obtained from viewing the video was found to be
helpful in determining the disposition in >80% of all instant
alerts or red flag events. An example of the additive value of
video, which pertains to the patient who is profiled in Figure 3,
is provided in Movies 1 to 3 in the in the Data Supplement.
Caregivers have reported nearly unanimous positive experiences with CHAMP. Of 30 families, 26 continued with
CHAMP tablet monitoring through the study. The remaining
4 families returned the CHAMP tablet and went back to monitoring using the notebook. When given the choice, 23 of 30
families who used both the notebook and the CHAMP tablet
stated that if they had to continue monitoring, they would use
the CHAMP tablet in preference to the 3-ring binder; 3 families had no preference and 4 families would use the notebook
in preference to the CHAMP tablet.
Our outcomes differ from those reported recently by Black
et al15 in recent study of a project for interstage monitoring.
They found that while remote monitoring was feasible in this
population, there were challenges with compliance and with the
reliability of hardware and software, and they terminated their
study earlier than planned because telemedicine did not affect
interstage mortality. In contrast, we have found no evidence of
increased admissions and a suggestion of decreased mortality.
We did not have any problems with families’ compliance. The
observed differences in outcomes may well reflect differences
relating to team structure and the specifics of the equipment used.

Estimated Costs of the Program
Year 1

Cost of tablet PCs

$600/tablet=$120 000

Cost of cellular coverage

Year 2

Year 3

$40/mo/tablet=$96 000

$40/mo/tablet=$96 000

$40/mo/tablet=$96 000

Total annual costs

$216 000

$216 000

$216 000

Cumulative costs

$216 000

$312 000

$408 000

400

400

400

No. of patients
Cumulative number of patients

400

800

1200

Cost per patient

$540

$390

$340

The estimated cost for 200 tablets over a 3-year period is $408 000. This would provide the ability to extend the program to
≈1200 interstage patients ($340/patient).
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To date, we have collected >27 000 data points on our 30
patients >18 months. Perhaps the most exciting feature of the
structure of CHAMP is that with this approach, wherein individual patient data is linked to clinical outcomes within the
HeartCenter database, each patient who is recruited becomes
part of a cohort of patients–in a manner akin to a registry–
albeit one with built-in, real-time analytic capabilities, as well
as the potential for predictive capabilities that are likely to
become more robust as data from more patients are collected
over time. Our vision for this aspect of CHAMP is that of a
live registry that would provide dynamic prediction of risk of
an adverse event for a given patient at a given time, based on
continuously updating and increasing data from the individual
patient as well as from the entire cohort.

Summary, Future Directions, and Challenges
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CHAMP represents a step in the evolution of the model of
care for chronic disease from episodic care toward the ideal
of continuously connected and continuously improving care.
We have successfully developed and implemented CHAMP
in our center with good results and planned to deploy the
platform in other centers. The development and implementation of CHAMP is currently supported by philanthropy, with
additional philanthropic support obtained to distribute 200
tablet PCs to sites around the country at no charge. We plan
to achieve this during the next 18 months. Our estimate for
the cost of hardware and cellular service for the program is
provided in Table 3. Costs for CHAMP development, program
administration, and data analytics are not included in this estimate. We assume that the tablet PCs will be reused during the
entire period, thus providing for coverage of 1 patient every
6 months, and that any losses because of damage or theft
will be minimal (we have had no such losses to date). This
should allow the accumulation of daily data at a rapid pace;
within one year, with full use of 200 tablets, we should have
≤200 years’ worth of daily monitoring data on >400 patients.
Deployment to multiple sites will test the scalability of the
platform and support generalizability of analyses from the
emerging registry. Although the integration between Heart
Center and our electronic medical record system has enabled
the creation of linkages between CHAMP data and clinical
events for individual patients in our center, the implementation
of CHAMP in other centers will be challenged by the need for
data entry to create such linkages with other electronic medical record systems. We have built an HL7 output that enables
all CHAMP data to be sent to any electronic medical record
system every 24 hours through the cloud-based system. The
development of robust databases and mechanisms for automated data export from the electronic medical record or other
enterprise databases would be a significant advance to minimize—if not eliminate—the need for redundant data entry.
We have already built in features to allow seamless export
of >98% of variables that are already being collected via
Research Electronic Data Capture for the NPC-QIC initiative,
thus decreasing the data burden for future sites participating
in the CHAMP program. We think that those types of linkages
will be crucial to progress toward developing more robust and
data-driven algorithms for predicting, and by extension, preventing interstage mortality and morbidity. We hope that the

perceived value of the information obtained from CHAMP
and the improved efficiency of the team would engage hospitals in supporting CHAMP without philanthropic support.
Our experience points to the need for studies to test the value
proposition to hospitals and payers, using robust study designs
that are designed to critically examine survival, resource utilization, and timeliness of care.
The development and evolution of wearable physiological
monitors for babies (or implantable monitors, placed at the
time of neonatal surgery), coupled with robust, unconditional
wireless capabilities for connection to the tablet PC, would
represent yet another step in the evolution toward continuously connected care. The use of machine learning as applied
to video of the baby could add another dimension to the potential for predictive algorithms. It would seem that the platform
that we have built for CHAMP has the potential for many
applications in various field of pediatric and adult medicine.
The user interface of the CHAMP tablet and the secure cloudbased data warehousing architecture that has been created are
customizable to enable entry of information that is pertinent
to other disease states. For example, the ability to record and
transmit blood pressure, weight, and heart rate may be of
value in adults with hypertension or heart failure. Similarly,
the ability to enter data from glucometers or spirometers may
enable improved monitoring for adults or children with diabetes mellitus or asthma. Pertinent instant alerts could be programmed for any of these conditions. When coupled with a
vigilant and responsive team of care-providers, the CHAMP
platform enables prompt and targeted clinical care, which may
prove to be important as medicine evolves to a value-based
model with a focus on outcomes.

Sources of Funding
This work was made possible by a generous grant from the Claire
Giannini Fund (http://www.clairegianninifund.org/).

Disclosures
None.

References
1. Norwood WI, Lang P, Hansen DD. Physiologic repair of aortic atresiahypoplastic left heart syndrome. N Engl J Med. 1983;308:23–26. doi:
10.1056/NEJM198301063080106.
2. Feinstein JA, Benson DW, Dubin AM, Cohen MS, Maxey DM, Mahle
WT, Pahl E, Villafañe J, Bhatt AB, Peng LF, Johnson BA, Marsden AL,
Daniels CJ, Rudd NA, Caldarone CA, Mussatto KA, Morales DL, Ivy
DD, Gaynor JW, Tweddell JS, Deal BJ, Furck AK, Rosenthal GL, Ohye
RG, Ghanayem NS, Cheatham JP, Tworetzky W, Martin GR. Hypoplastic
left heart syndrome: current considerations and expectations. J Am Coll
Cardiol. 2012;59(suppl 1):S1–S42. doi: 10.1016/j.jacc.2011.09.022.
3. Ohye RG, Sleeper LA, Mahony L, Newburger JW, Pearson GD, Lu M,
Goldberg CS, Tabbutt S, Frommelt PC, Ghanayem NS, Laussen PC,
Rhodes JF, Lewis AB, Mital S, Ravishankar C, Williams IA, DunbarMasterson C, Atz AM, Colan S, Minich LL, Pizarro C, Kanter KR,
Jaggers J, Jacobs JP, Krawczeski CD, Pike N, McCrindle BW, Virzi L,
Gaynor JW; Pediatric Heart Network Investigators. Comparison of shunt
types in the Norwood procedure for single-ventricle lesions. N Engl J
Med. 2010;362:1980–1992. doi: 10.1056/NEJMoa0912461.
4. Centers for Disease C and Prevention. Hospital stays, hospital charges,
and in-hospital deaths among infants with selected birth defects–United
States, 2003. MMWR Morb Mortal Wkly Rep. 2007;56:25–29.
5. Pearl JM, Nelson DP, Schwartz SM and Manning PB. First-stage palliation for hypoplastic left heart syndrome in the twenty-first century. Ann
Thorac Surg. 2002;73:331–339; discussion 339–340.

Shirali et al   Teams and Technology to Improve Outcomes   311
6. Ghanayem NS, Hoffman GM, Mussatto KA, Cava JR, Frommelt PC,
Rudd NA, Steltzer MM, Bevandic SM, Frisbee SS, Jaquiss RD, Litwin
SB, Tweddell JS. Home surveillance program prevents interstage
mortality after the Norwood procedure. J Thorac Cardiovasc Surg.
2003;126:1367–1377. doi: 10.1016/S0022.
7. Schidlow DN, Gauvreau K, Patel M, Uzark K, Brown DW. Site of interstage care, resource utilization, and interstage mortality: a report from
the NPC-QIC registry. Pediatr Cardiol. 2015;36:126–131. doi: 10.1007/
s00246-014-0974-7.
8. Ghanayem NS, Allen KR, Tabbutt S, Atz AM, Clabby ML, Cooper DS,
Eghtesady P, Frommelt PC, Gruber PJ, Hill KD, Kaltman JR, Laussen
PC, Lewis AB, Lurito KJ, Minich LL, Ohye RG, Schonbeck JV, Schwartz
SM, Singh RK, Goldberg CS; Pediatric Heart Network Investigators.
Interstage mortality after the Norwood procedure: results of the multicenter Single Ventricle Reconstruction trial. J Thorac Cardiovasc Surg.
2012;144:896–906. doi: 10.1016/j.jtcvs.2012.05.020.
9. Schidlow DN, Anderson JB, Klitzner TS, Beekman RH III, Jenkins KJ,
Kugler JD, Martin GR, Neish SR, Rosenthal GL, Lannon C; JCCHD
National Pediatric Cardiology Quality Improvement Collaborative.
Variation in interstage outpatient care after the Norwood procedure:
a report from the Joint Council on Congenital Heart Disease National
Quality Improvement Collaborative. Congenit Heart Dis. 2011;6:98–
107. doi: 10.1111/j.1747-0803.2011.00509.x.
10. Hsu DT, Zak V, Mahony L, Sleeper LA, Atz AM, Levine JC, Barker PC,
Ravishankar C, McCrindle BW, Williams RV, Altmann K, Ghanayem
NS, Margossian R, Chung WK, Border WL, Pearson GD, Stylianou MP,
Mital S; Pediatric Heart Network Investigators. Enalapril in infants with

11.

12.

13.

14.

15.
16.

single ventricle: results of a multicenter randomized trial. Circulation.
2010;122:333–340. doi: 10.1161/CIRCULATIONAHA.109.927988.
Anderson JB, Beekman RH III, Kugler JD, Rosenthal GL, Jenkins
KJ, Klitzner TS, Martin GR, Neish SR, Darbie L, King E, Lannon C;
National Pediatric Cardiology Quality Improvement Collaborative. Use
of a learning network to improve variation in interstage weight gain after the Norwood operation. Congenit Heart Dis. 2014;9:512–520. doi:
10.1111/chd.12232.
Anderson JB, Beekman RH III, Kugler JD, Rosenthal GL, Jenkins KJ,
Klitzner TS, Martin GR, Neish SR, Brown DW, Mangeot C, King E,
Peterson LE, Provost L, Lannon C. Improvement in Interstage Survival
in a National Pediatric Cardiology Learning Network. Circ Cardiovasc
Qual Outcomes. 2015;27:555–562.
Clauss SB, Anderson JB, Lannon C, Lihn S, Beekman RH, Kugler JD,
Martin GR. Quality improvement through collaboration: the National
Pediatric Quality improvement Collaborative initiative. Curr Opin
Pediatr. 2015;27:555–562. doi: 10.1097/MOP.0000000000000263.
Cross R, Steury R, Randall A, Fuska M, Sable C. Single-ventricle
palliation for high-risk neonates: examining the feasibility of an automated home monitoring system after stage I palliation. Future Cardiol.
2012;8:227–235. doi: 10.2217/fca.12.9.
Black AK, Sadanala UK, Mascio CE, Hornung CA, Keller BB. Challenges
in implementing a pediatric cardiovascular home telehealth project.
Telemed J E Health. 2014;20:858–867. doi: 10.1089/tmj.2013.0343.
Mobile Medical Applications: Guidance for Industry and Food and Drug
Administration staff. 2015. http://www.fda.gov/downloads/Medical
Devices/.../UCM263366.pdf. Accessed April 28, 2016.

Downloaded from http://ahajournals.org by on July 26, 2019

